

RECEIVED
CENTRAL FAX CENTER
OCT 25 2006In re Application of: Wu et al.
Serial No.: 10/649,495
Filed: 08/27/2003


- 2 -

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application (note that amendments are highlighted in **bold**):

Claims 1-4 (cancelled)

5. (original) A compound represented by the structural formula



formula II

or a pharmaceutically acceptable salt or solvate thereof, wherein

p is 0, 1 or 2 and when p is 0, the carbons to which (V)_p is shown connected are not linked to each other but are linked to hydrogen;

G is hydrogen, halo, alkyl, alkylthio, nitro, nitrile, hydroxy, alkoxy, alkylsulfinyl, alkylsulfonyl, trifluoromethyl or trifluoromethoxy;

V is -CH₂-;

W is selected from the group consisting of O, S, NH and N(alkyl);

Z is selected from the group consisting of NH, N(alkyl), S and O;

R¹ is hydrogen, alkyl, allyl, cycloalkyl or cycloalkyl(alkyl);

R² is hydrogen or 1 to 4 substituents which can be the same or different, each R² being independently selected from the group consisting of halogen, alkyl, alkylthio, alkylsulfonyl, hydroxy, alkoxy, trifluoromethyl, trifluoromethoxy, aryl, -CH=O, -NO₂, -NR¹¹R¹², CN, R¹⁰-substituted aryl, heteroaryl, -C(O)OR⁸, -C(O)NR³R⁴, -S(O)₂NR³R⁴, -C(R⁷R⁸)NR⁵R⁶, -C(R⁷)=NOR⁴ and -C(R⁷R⁸)OR⁶;

R³ is aryl, R¹⁰-substituted aryl, arylalkyl, heteroaryl, alkyl or hydrogen;

R⁴ is aryl, R¹⁰-substituted aryl, heteroaryl, alkyl or hydrogen,

In re Application of: Wu et al.
Serial No.: 10/649,495
Filed: 08/27/2003

- 3 -

or R^3 , R^4 and N of $-NR^3R^4$ together can be joined together to form a ring selected from the group consisting of azetidine, R^8 -substituted azetidine, pyrrolidine, R^8 -substituted pyrrolidine, piperidine, R^8 -substituted piperidine, piperazine, R^8 -substituted piperazine, morpholine and R^8 -substituted morpholine;

R^5 is alkyl, arylalkyl, $-C(O)NR^3R^4$, $-S(O)_2NR^3R^4$, $-S(O)_2R^8$, $-C(O)R^8$, $-C(O)OR^8$ or $-R^9O$ -alkyl;

R^6 is hydrogen, alkyl, aryl, R^{10} -substituted aryl, heteroaryl or arylalkyl, or R^5 , R^6 and N in $-NR^5R^6$ together can be joined together to form a ring selected from the group consisting of azetidine, R^8 -substituted azetidine, pyrrolidine, R^8 -substituted pyrrolidine, piperidine, R^8 -substituted piperidine, piperazine, R^8 -substituted piperazine, morpholine and R^8 -substituted morpholine;

R^7 is hydrogen, alkyl, aryl or arylalkyl;

R^8 is hydrogen, aryl, alkyl, arylalkyl or heteroaryl;

R^9 is hydrogen, alkyl, aryl, R^{10} -substituted aryl, heteroaryl or arylalkyl;

R^{10} is selected from the group consisting of aralkyl, heteroaralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, Y_1Y_2N -, Y_1Y_2N -alkyl-, $Y_1Y_2NC(O)$ - and $Y_1Y_2NSO_2$ -, wherein Y_1 and Y_2 may be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl;

R^{11} is hydrogen, alkyl or arylalkyl;

R^{12} is $-C(O)R^{13}$, $-S(O)_2R^{13}$, $-C(O)NR^3R^4$ or $-C(O)OR^{13}$;

and

R^{13} is alkyl, aryl, R^{10} -substituted aryl, heteroaryl or arylalkyl.

6. (original) The compound of claim 5 wherein

G is halo;

R^1 is hydrogen, alkyl, cyclopropyl or cyclopropylmethyl;

R^2 is hydrogen;










and

W is S or O.

- 4 -

- Claim 9 (cancelled)**


-



and

In re Application of: Wu et al.
Serial No.: 10/649,495
Filed: 08/27/2003

- 5 -



or a pharmaceutically acceptable salt or solvate thereof.

Claim 11 (cancelled)

12. (original) A method of treating a metabolic disorder, an eating disorder or diabetes comprising administering to a patient a therapeutically effective amount of at least one compound of claim 5 to a patient in need of such treatment.

Claim 13 (cancelled)

14. (original) A method of treating a metabolic disorder, an eating disorder or diabetes comprising administering to a patient a therapeutically effective amount of at least one compound of claim 10 to a patient in need of such treatment.

Claims 15 and 16 (cancelled)

17. (original) The method of claim 12 wherein said eating disorder is hyperphagia.

18. (original) The method of claim 12 wherein said metabolic disorder is obesity.

Claims 19-23 (cancelled)

24. (original) A method for treating a human afflicted with a disorder selected from the group consisting of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, trichotillomania

In re Application of: Wu et al.
Serial No.: 10/649,495
Filed: 08/27/2003

- 6 -

and autism, said method comprising administering an effective amount of the compound of claim 5.

Claim 25 (cancelled)

26. (original) The method of claim 24, wherein the eating disorders are selected from the group consisting of anorexia nervosa, bulimia, and binge eating.

Claim 27 (cancelled)

28. (amended) The method for treating a human afflicted with a disorder of claim 24, wherein the disorder is an impulse control disorder from the group consisting of pathological gambling, compulsive buying, and sexual compulsion.

Claims 29-32 (cancelled)

33. (original) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 5 in combination with at least one pharmaceutically acceptable carrier.

Claim 34 (cancelled)

35. (original) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 10 in combination with at least one pharmaceutically acceptable carrier.

Claim 36 (cancelled)


37. (original) A process for making a pharmaceutical composition comprising combining at least one compound of claim 5, and at least one pharmaceutically acceptable carrier.

In re Application of: **Wu et al.**
Serial No.: **10/649,495**
Filed: **08/27/2003**

- 7 -

Claim 38 (cancelled)

39. (original) A compound of claim 5 having the absolute stereochemistry as shown in the formula



or a pharmaceutically acceptable salt or solvate thereof.